Scientists blueprint antimicrobial candidate that may stem post-antibiotic tide

February 18, 2016
The antibiotic, globomycin, shuts down lipoprotein maturation by blocking the active site of the processing enzyme, LspA. Researchers hope their blueprint of LspA-globomycin will inform drug design so that analogues may be developed to fight a plethora of common but devastating infections. Credit: Martin Caffrey, Trinity College Dublin.

Scientists at Trinity College Dublin have provided the first crystal clear molecular blueprint of Globomycin - an antibacterial candidate with promise in stemming the onrushing post-antibiotic tide.

Crucially, their blueprint may aid the design of better globomycin analogues and the exploration of thousands of other potential new antibiotic solutions to common but devastating infections.

With antimicrobial resistance on the rise, the World Health Organization has advised that a post-antibiotic era, in which minor injuries and common infections could prove fatal, is looming. New drugs are badly needed.

Globomycin attracted attention as an antibacterial candidate of significant promise more than a decade ago, because it inhibits a key enzyme LspA and thus the production of many cell wall proteins with critical roles in bacterial physiology, pathogenicity and antibiotic resistance. If delivered effectively, Globomycin and Globomycin-like drugs could knock out a variety of bacterial infections.

However, the progression of earlier studies stagnated, partly because researchers did not possess the all-important high-res blueprints with which to guide further drug development. That hurdle has now been removed as that very blueprint has just been published in a landmark paper in leading international journal Science.

The video will load shortly
The antibiotic globomycin (grey sticks) shuts down lipoprotein maturation by blocking the active site of the processing enzyme LspA. Credit: Martin Caffrey, Trinity College Dublin.

Professor of Membrane Structural and Functional Biology at Trinity College Dublin, Martin Caffrey, said: "Our LspA-globomycin blueprint can be used to inform the design of globomycin derivatives or analogues with improved binding, efficacy, selectivity and pharmacokinetic properties."

"The molecular form of the complex makes it a suitable target with which to explore the thousands of inhibitors developed for other medically relevant aspartyl protease enzymes. These include drugs that treat high blood pressure and HIV AIDS."

The blueprint might also be used to design entirely targeted specifically at the chemical constellation of the enzyme's active site in the bacteria Pseudomonas aeruginosa. However, it may be that blueprints of LspA from other pathogenic bacterial species such as Enterococcus, Staphylococcus (MRSA), Klebsiella, Acinetobacter and Enterobacter should be the immediate focus of efforts at the design of species-specific antibiotic drugs.

The video will load shortly
Immature lipoprotein (grey) in the active site of the processing enzyme LspA primed to undergo maturation. Credit: Martin Caffrey, Trinity College Dublin.

Such so-called narrow spectrum antimicrobials are more attractive because they are less likely to promote a generalised response.

Professor Caffrey added: "What is especially exciting is that the blueprint makes it hard to conceive bacteria developing resistance to Globomycin or newly developed analogues."

"Globomycin and its enzyme target are networked to such a degree that any mutation perturbing the drug's interaction would also likely impact on how the bacteria functions. Antibiotics that do not elicit resistance are invaluable to medicine, and this work might inspire the design of such drugs."

In a twist of evolutionary fate, Globomycin is a natural antimicrobial produced by bacteria of the Actinomycete type, which means we are effectively drawing up battle plans to wage war against bacterial infections by borrowing from the arsenal of other bacteria. Lessons in developing effective drugs should be learned from this reality.

Explore further: Linking antibiotic to antibody found able to kill MRSA hiding in mice cells

More information: Structural basis of lipoprotein signal peptidase II action and inhibition by the antibiotic globomycin," Science, DOI: 10.1126/science.aad3747

Related Stories

Immunologists unearth key piece of MRSA vaccine puzzle

November 5, 2015

Immunologists from Trinity College Dublin have unearthed a key piece of the MRSA vaccine puzzle by identifying specific 'helper' cells whose role in the immune response is critical in affecting infection outcomes.

New weapons to battle bacterium behind ulcers

November 24, 2015

Helicobacter pylori is a bacteria that lives in the gut of more than 50 per cent of the world's population, and is the most common bacterial infection worldwide. It is responsible for most peptic ulcers and is a significant ...

Recommended for you

Isolation of Fe(IV) decamethylferrocene salts

August 29, 2016

(Phys.org)—Ferrocene is the model compound that students often learn when they are introduced to organometallic chemistry. It has an iron center that is coordinated to the π electrons in two cyclopentadienyl rings. (C5H5- ...

Bringing artificial enzymes closer to nature

August 29, 2016

Scientists at the University of Basel, ETH Zurich, and NCCR Molecular Systems Engineering have developed an artificial metalloenzyme that catalyses a reaction inside of cells without equivalent in nature. This could be a ...

New method developed for producing some metals

August 25, 2016

The MIT researchers were trying to develop a new battery, but it didn't work out that way. Instead, thanks to an unexpected finding in their lab tests, what they discovered was a whole new way of producing the metal antimony—and ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.